Document:

EX-4.4

 Exhibit 4.4 

June 30, 2017 

Shareholders Agreement 
  

 
  

AnPac Bio-Medical Science Co., Ltd. 

 
  

A limited liability company incorporated in the British Virgin Islands 

 Shareholders Agreement 

The Shareholders Agreement (this “Agreement”) is signed by the following parties on June 30, 2017: 

 

	(1)	 AnPac Bio-Medical Science Co., Ltd., a limited liability company
duly established and validly existing in the British Virgin Islands, with its registered address at SHRM Trustees (BVI) Limited of Trinity Chambers, P.O. Box 4301, Road Town, Tortola, British Virgin Islands (the “Company”);

  

	(2)	 Dr. Chris Chang Yu, U.S. Citizen, ID number:[    ];

  

	(3)	 CRS Holdings INC., a limited liability company duly established and validly existing in the British
Virgin Islands, with its registered address at SHRM Trustees (BVI) Limited of Trinity Chambers, P.O. Box 4301, Road Town, Tortola, British Virgin Islands (“CRS Company”); 

 

	(4)	 Ms. Lin Yu, Chinese citizen, ID number: [    ];

  

	(5)	 Zhejiang AnPac Bio-Medical Science Co., Ltd., a limited
liability company legally established and validly existing in China, with its registered address at Room 108, No.131 Nanshan Yuanyuan Middle Road, Bihu Town, Liandu District, Lishui City, Zhejiang Province (“Lishui Company”);

  

	(6)	 Changhe Bio-Medical Science (Yangzhou) Co., Ltd., a limited
liability company duly established and validly existing in China, with its registered address at 3rd Floor, Building 9, Jiangsu Information Service Industry Base (Yangzhou) (“Yangzhou Company”); 

 

	(7)	 Changwei System Technology (Shanghai) Co., Ltd., a limited liability company legally established and
validly existing in China, with its registered address at Room 316, No. 105 Sinan Road, Huangpu District, Shanghai (“Changwei Company”); 

 

	(8)	 AnPac Bio-Medical Science (Shanghai) Co., Ltd., a limited
liability company legally established and validly existing in China, with its registered address at Room 301-346, Building 1, No. 400, Fangchun Road, Zhangjiang
Hi-Tech Park, Shanghai (“AnPac Shanghai Company”); 

  

	(9)	 Shanghai Xinshenpai Technology Co., Ltd., a limited liability company legally established and validly
existing in China, with its registered address at Room 316, No. 105 Sinan Road, Huangpu District, Shanghai (“Xinshenpai Company”); and 

  

	(10)	 Lishui AnPac Medical Laboratory Co., Ltd., a medical institution legally established and validly
existing in China, with its registered address at No. 801, Bixing Street, Bihu Town, Liandu District, Lishui City, Zhejiang Province (“Medical Laboratory”); and 

 

	(11)	 Chengdu Lipaishen Bio-Medical Science Co., Ltd., a limited
liability company legally established and validly existing in China, with its registered address at Building 1, No. 9, Shaocheng Road, Qingyang District, Chengdu City (“Chengdu Company”); and 

  
 1 

	(12)	 ANPAC TECHNOLOGY USA CO., LTD., a limited liability company legally established and validly existing in
the United States, with its registered address at 1209 ORANGE STATE, WILMINGTON DE 19801 (“AnPac U.S.”); 

  

	(13)	 ZHANGJIANG GU KE COMPANY LIMITED, a limited liability company legally established and validly existing
in the British Virgin Islands, with its registered address at Commence Chambers, P.O.Box 2208, Road Town, Tortola, British Virgin Islands (“Zhangjiang Science Investment”); 

 

	(14)	 Jiaxing Zhijun Sihang Investment Partnership (Limited Partnership), a limited liability company legally
established and validly existing in China, with its registered address at Room 113 -7, Dongfang Building, 100 Zhuyuan Road, Nanhu District, Jiaxing City, Zhejiang Province (“Zhijun
Investment”). 

 In this Agreement, Chris Chang Yu and CRS Company are hereinafter referred to individually as the
“Founder” and collectively as the “Founders”; Founders and Ms. Lin Yu are hereinafter referred to individually as the “Existing Major Shareholder” and collectively as the “Existing Major
Shareholders”; Zhangjiang Science Investment and Zhijun Investment are referred to collectively as the “Investors” and individually as the “Investor”; Existing Major Shareholders and other Shareholders of
the Company shall be collectively referred to as the “Existing Shareholders”; Lishui Company, Yangzhou Company, Changwei Company, AnPac Shanghai Company, Xinshenpai Company, Medical Laboratory, Chengdu Company and AnPac U.S. are
hereinafter referred to individually as the “Domestic and Foreign company” and collectively as the “Domestic and Foreign Companies”; The Company and Domestic and Foreign Companies and all other direct or indirect,
current or future Subsidiaries of the above companies are referred to individually as “Group Company” and collectively as the “Group Companies”; The parties to this Agreement are referred to collectively as the
“Parties” and individually as the “Party”. 
 Preface 

Whereas, the Company and Zhijun Investment signed a Share Subscription Agreement (the “Subscription Agreement”) on June 30, 2017; 

Whereas, the Company and Zhangjiang Science Investment and other Related Parties signed a Shareholders Agreement and its Supplementary Agreement (the
“Original Shareholders Agreement”) on June 29, 2015; 
 For the purpose of agreeing on the shareholder rights of Zhijun Investment,
the Parties hereby agree as follows: 
  

	1.	 DEFINITION 

  

	1.1	 Definition.    Unless otherwise defined in this Agreement, the extrabold terms in
this Agreement shall have the following meanings: 

  
 2 

	 “AnPac Shanghai Company” 
	It shall have the meaning of the preceding provisions. 

  

	 “Applicable Law” 
	Refers to any Person, suitable for the Person or any of its assets or business, whether it be on or after the date of this agreement valid and amended from time to time or any of the constitution, treaty, statute, law, statute, decree, norm,
regulation, judgment, general law rule, order, edict, adjudication, prohibition, Government Approval, approval, grant, franchise, license, consent, order, requirement, or any other government restriction of any Government Agency or any similar form
of decree, or any decision made by it, or the interpretation and implementation of any of the foregoing. 

  

	 “Board of Directors” 
	Refers to the board of directors of the Company. 

  

	 “Changwei Company” 
	It shall have the meaning of the preceding provisions. 

  

	 “China” 
	Refers to the People’s Republic of China, but for the purposes of this Agreement, it does not include Hong Kong, Macao Special Administrative Region and Taiwan. 

 

	 “Company” 
	It shall have the meaning of the preceding provisions. 

  

	 “Confidential Information” 
	It shall have the meaning set forth in Clause 7.1. 

  

	 “Contracts” 
	Refers to any agreement, arrangement, commitment, covenant, franchise, indemnity, contract, instrument, lease, license, permission or binding memorandum of understanding (whether in writing or not). 

 

	 “Control” 
	(Including the relevant meanings for “controlling”, “controlled” and “jointly controlled”) in the case of any person, refers to the right of any Person to directly or indirectly guide the
management or policy of that Person (related to operational control, financial control or other control) whether through the ownership of voting securities or through contracts or otherwise. 

 

	 “Disposing Shareholder” 
	Refers to any Existing Major Shareholder or assignee of his/her Equity Securities. 

  

	 “Dispute” 
	It shall have the meaning set forth in Clause 11.3(a). 

  

	 “Equity Securities” 
	Refers to all Ordinary Shares or securities convertible or exchangeable into Ordinary Shares of the Company. 

  

	 “Existing Major Shareholder” and “Existing Major Shareholders” 
	It shall have the meaning of the preceding provisions. 

  
 3 

	 “Existing Shareholders” 
	It shall have the meaning of the preceding provisions. 

  

	 “Founder” and “Founders” 
	It shall have the meaning of the preceding provisions. 

  

	 “Group Company” and “Group Companies” 
	They shall have the meaning of the preceding provisions. 

  

	 “Government Agency” 
	Refers to any government or its political branches, whether at the federal, central, state, provincial, municipal or local levels, regardless of administrative, legislative or judicial nature, including any representative office, authority,
council, bureau, committee, court, department or other organ. 

  

	 “Government Approval” 
	Refers to any consent, approval, authorization, exemption, permit, grant, franchise, allowance, permission, exemption or order of a Government Agency, and registration, certification, declaration, filing, reporting or notification to a
Government Agency. 

  

	 “Hong Kong” 
	Refers to the Hong Kong Special Administrative Region of China. 

  

	 “Information Right” 
	It shall have the meaning set forth in Clause 2.1(e). 

  

	 “Inspection Right” 
	It shall have the meaning set forth in Clause 2.2. 

  

	 “Investor” and “Investors” 
	It shall have the meaning of the preceding provisions. 

  

	 “Knowledge” 
	When referring to a Person’s “knowledge”, it refers to the actual knowledge of the Person, and the knowledge should be known to the Person as a prudent business Person after proper consultation and due diligence in managing
his/her business. These investigations include appropriate consultation with the management, directors, key employees and professional consultants (including lawyers, accountants and consultants) of the Person and his/her Related Parties.

  

	 “Lishui Company” 
	It shall have the meaning of the preceding provisions. 

  
 4 

	 “Loss” 
	Refers to all direct or indirect losses, liabilities, damages, deficiencies, value impairments, litigation, liabilities, duties, benefits, interests, fines, fees, judgments or settlements of any nature or kind, including all related costs and
expenses, including but not limited to reasonable attorney fees and expenses of any kind or nature, legal fees, settlement fees and investigation costs, whether legal or in an equity law, known or unknown, foreseeable or unforeseen.

  

	 “Material Adverse Effects” 
	Refers to the material adverse effects of a particular Person’s condition (financial or other conditions), his/her associated assets, operating results or prospects, or business (currently or intended to be carried out). 

 

	 “New Shares” 
	It shall have the meaning set forth in Clause 3.2. 

  

	 “Notice of Exercising Right of First Refusal” 
	It shall have the meaning set forth in Clause 3.3. 

  

	 “Notice of Transfer” 
	It shall have the meaning set forth in Clause 4.2(a). 

  

	 “Ordinary Shareholder” 
	Refers to a holder of Ordinary Shares. 

  

	 “Original Shareholders Agreement” 
	It shall have the meaning set forth in the Preface. 

  

	 “Ordinary Shares” 
	Refers to the Company’s ordinary shares, with a par value of US$1.00 each. 

  

	 “Organizational Document” 
	Refers to, in relation to any Person, a certificate of registration, memorandum of association, articles of association, joint venture agreement, shareholders’ agreement or similar organizational document of such Person. 

 

	 “Party” and “Parties” 
	Shall have the meanings set forth in the preceding provisions, respectively. 

  

	 “Persons” 
	Shall be construed as broadly as possible and shall include individuals, partnerships (including limited liability partnerships), companies, associated companies, joint stock companies, limited liability companies, trusts, joint ventures
(including Sino-foreign joint ventures and Sino-foreign cooperative ventures), non-corporate organizations and Government Agencies. 

 

	 “Preemptive Period” 
	It shall have the meaning set forth in Clause 4.1(b)(i). 

  

	 “Preemptive Right” 
	It shall have the meaning set forth in Clause 4.1(b)(i). 

  

	 “Preface” 
	Refers to the preface of this Agreement. 

  
 5 

	 “Price Per Share for Investors” 
	Refers to Price Per Share for Zhijun Investment or Price Per Share for Zhangjiang Science Investment. 

  

	 “Price Per Share for Zhangjiang Science Investment” 
	Refers to the Price Per Share of Zhangjiang Science Investment which is based on its Share Subscription Agreement signed with the Company, Chris Chang Yu and other interested parties on June 29, 2015, i.e. RMB1,800.67. 

 

	 “Price Per Share for Zhijun Investment” 
	Refers to the price obtained by the subscription price divided by the number of the subscribed shares, i.e. RMB6,761.33. 

  

	 “Priority Subscription Notice” 
	It shall have the meaning set forth in Clause 3.3(a). 

  

	 “Priority Subscription Period” 
	It shall have the meaning set forth in Clause 3.3(a). 

  

	 “Purchase Notice” 
	It shall have the meaning set forth in Clause 4.2(b)(i). 

  

	 “Qualified Public Offering” 
	The Company or any other Group Company shall be listed on a stock exchange in China, Hong Kong or other internationally recognized stock exchange and shall publicly issue Ordinary Shares or shares of the Group Company in accordance with the
securities trading laws and regulations of the applicable jurisdiction. 

  

	 “Related Parties” 
	In the case of a specific Person, it refers to (a) when he/she is a natural person, his/her spouse and his/her immediate family members (whether blood relatives or adoption) or any trust established and maintained solely for the benefit of
the person, his/her spouse and/or such immediate family members; and (b) when it is any person, directly or indirectly through one or more media, controlling the specific Person, being controlled by the specific person or being controlled
jointly with the specific Person. 

  

	 “Ren Min Bi” or “RMB” 
	Refers to the lawful currency of China. 

  

	 “Right of First Refusal” 
	It shall have the meaning set forth in Clause 3.1. 

  

	 “Senior Executives” 
	Refers to the material adverse effects of a particular Person’s condition (financial or other conditions), his/her associated assets, operating results or prospects, or business (currently or intended to be carried out). 

 

	 “Shareholders” 
	Refers to any Person who holds Equity Securities. 

  

	 “Sold Shares” 
	It shall have the meaning set forth in Clause 4.2(a). 

  
 6 

	 “Subsidiary” 
	Refers to in relation to the specific Person, any other non-natural Person controlled by that specific Person. 

  

	 “This Agreement” 
	It shall have the meaning of the preceding provisions. 

  

	 “Transfer” 
	Refers to the transfer, sale, guarantee, encumbrance, mortgage, pledge, donation or other disposition of any or all of the shares of a particular Person, whether voluntary or involuntary (including but not limited to those arising from divorce,
separation, bankruptcy or other proceedings, or death) or by operation of law. 

  

	 “US$” 
	Refers to the lawful currency of the United States. 

  

	 “Working Day” 
	Refers to any day on which banks in the British Virgin Islands and China normally operate (except Saturdays and Sundays and public holidays in the British Virgin Islands or China). 

 

	 “Xinshenpai Company” 
	It shall have the meaning of the preceding provisions. 

  

	 “Yangzhou Company” 
	It shall have the meaning of the preceding provisions. 

  

	1.2	 Interpretation. For all purposes of this Agreement, except as expressly provided herein, (a) The
terms defined in the Clause 1.1 shall have the meanings ascribed to them in this Clause 1.1 and shall include the plural and the singular, (b) All accounting terms not otherwise defined in this Agreement shall have the meaning given by the
Chinese Accounting Standards, (c) All designated “Clauses” and “Sub-Clauses” referenced in this Agreement shall mean the Clauses and
Sub-Clauses identified in the Main Body of this Agreement, (d) A gender or neutral pronoun shall include other appropriate forms of the pronoun, (e) The terms “in this Agreement”,
“of this Agreement” and “under this Agreement” and other terms of similar meaning refer to this Agreement as a whole and not designate any particular clause or sub-clause,
(f) Unless otherwise expressly stated, all appendices specified by reference to this Agreement refer to appendices to this Agreement, (g) The term “including” and other similar words shall be deemed to be immediately
followed by “but not limited to”, whether or not they are actually immediately followed by such words or words of similar meaning, (h) The headings of the terms of this Agreement are for identification and reference only and
shall not be used to interpret this Agreement, (i) Any “Party” or any other Person referred to in this Agreement shall be construed as including successors to his/her rights, his/her permitted successors and permitted
assignees, and (j) Any agreement or instrument referred to in this Agreement shall include its amended or substituted text. This Agreement shall be interpreted literally. 

 

	2.	 INFORMATION RIGHT; INSPECTION RIGHT 

 

	2.1	 Information Right. The Company warrants and agrees that, as of the date of this Agreement, it will
deliver to each Investor: 

  

	 	(a)	 The annual consolidated financial statements of each Group Company prepared in accordance with the Chinese
Accounting Standards and other applicable local accounting terms and rules and audited by an accounting firm as agreed by the Company and the Investors shall be delivered within one hundred and twenty (120) days after the end of each fiscal
year; 

  
 7 

	 	(b)	 The unaudited quarterly consolidated financial and management statements of Group Companies prepared in
accordance with Chinese accounting standards and other applicable local accounting terms and rules shall be delivered within twenty-eight (28) days after the end of six months; 

 

	 	(c)	 An annual business plan and monthly budget for each Group Company for the following fiscal year shall be
delivered within thirty (30) days prior to the end of each fiscal year; 

  

	 	(d)	 Notice of all litigations, prosecutions, claims, judicial proceedings, investigations, inquiries or incidents
that may have a Material Adverse Effect on any Group Company or any of its Related Parties and their ownership of or rights in their respective businesses, real property, assets or property; and 

 

	 	(e)	 Other information reasonably requested to be delivered by each Investor upon written request by them
(collectively referred to as the “Information Right”). 

 All financial statements to be provided to each
Investor in accordance with this Clause 2.1 shall include income statements, balance sheets and cash flow statements for the relevant periods and for the current fiscal year prepared in accordance with the Chinese Accounting Standards and other
applicable local accounting terms and rules. 
  

	2.2	 Inspection Right. Each Group Company further warrants and agrees that, as of the date of this Agreement,
each Investor and his or her authorized representative shall have the right (a) to inspect, extract and photocopy the facilities, records and books of account of the Group Company under normal working hours and reasonable and without prejudice
to the normal operation of the Group Company after reasonable prior notice to the Group Company concerned, and (b) to discuss the business, operation and conditions of any Group Company with their respective directors, officers, employees,
accountants, legal advisers and investment banks, without prejudice to the normal operation of the Group Company (the “Inspection Right”). Each Group Company will provide and cause its subsidiaries to provide to each Investor and
his or her authorized representative such information as each Investor may reasonably require from time to time. Each Group Company shall provide all reasonable support to effectively assist in such investigations. Any Investor shall have the right
to require the Group Company to be notified 30 days in advance and to be audited by an accounting firm approved by such Investor, but not more than once a year, at the expense of the Investor, provided that the Investor does not interfere with the
normal operation of the Group Company and under the reasonable circumstance. 

  

	2.3	 Termination of Rights. The Information Right and the Inspection Right shall be terminated at the time of
the completion of the Qualified Public Offering and delivery. 

  

	3.	 RIGHT OF FIRST REFUSAL 

  
 8 

	3.1	 Overview. Each Investor shall have priority to purchase all (or any part thereof) of any New Shares
issued by the Company from time to time after the date of this Agreement (the “Right of First Refusal”). 

  

	3.2	 New Share. “New Share” refers to any Equity Securities of the Company (whether or not
it is now an authorized share capital) and rights, options or warrants of any type of securities that may be purchased or converted or exchanged for Equity Securities of the Company. While the term “New Share” shall not include:

  

	 	(a)	 any Ordinary Shares sold or issued under the Subscription Agreement; 

 

	 	(b)	 any securities (including any repurchased shares) issued under the Employee Option Scheme of the Company to
officers, directors, employees and advisers of any Group Company; 

  

	 	(c)	 any securities issued in a Qualified Public Offering; 

 

	 	(d)	 any securities issued as a result of any share splitting or dividend distribution, recapitalization or similar
transaction subject to a pro rata adjustment; and 

  

	 	(e)	 any securities issued for the purpose of the acquisition in good faith of another company or entity or other
reorganization activity by the Company through merger, consolidation, purchase of all or substantially all of its assets (the relevant conditions of which shall be approved by the Board of Directors). 

 

	3.3	 Procedure. 

  

	 	(a)	 Priority Subscription Notice. If the Company plans to issue New Shares (whether through a single
transaction or a series of related transactions), it shall give each Investor a written notice of its intention to issue such New Shares (the “Priority Subscription Notice”) describing the number, type, price of the New Shares and
the general terms and conditions under which the Company intends to issue such New Shares. Each Investor may, within five (5) Working Days (the “Priority Subscription Period”) from the date of receipt of the Priority
Subscription Notice, agree in writing to purchase the amount of New Shares to be issued at the prices and terms and conditions set out in the Priority Subscription Notice by giving a written notice to the Company (the “Notice of Exercising
Right of First Refusal”) stating the number of New Shares to be purchased. If any investor fails to give a Notice of Exercise of Right of First Refusal during the Priority Subscription Period, such Investor shall be deemed to have waived
his Right of First Refusal. The Board of Directors of the Company shall not pass any resolution enabling the Company to issue any New Shares under the Right of First Refusal to any third person that have not been exercised or waived by the Investors
in accordance with the provisions of this Clause 3. The maximum amount of New Shares that any investor is entitled to subscribe for is: New Shares x (the number of Ordinary Shares held by the Investor at the time of the Company’s Priority
Subscription Notice ÷ the sum of all Ordinary Shares issued at the time of the Company’s Priority Subscription Notice). 

  
 9 

	3.4	 Failure to Exercise. Upon expiration of the Priority Subscription Period, and in the case that the New
Shares are not fully subscribed by each Investor through the Right of First Refusal, the Company shall, within ninety (90) days after the expiration of the Priority Subscription Period, sell the New Shares described in the Priority Subscription
Notice (in respect of the unexercised portion of the Right of First Refusal) at a price equal to or higher than the price stated in the Priority Subscription Notice, or for non-price terms, on terms no more
favorable than those set forth in the Priority Subscription Notice. If the Company fails to complete the issue and sale of the New Shares within ninety (90) days after the expiration of the Priority Subscription Period, or the Company intends
to issue and sell the New Shares on terms more favorable than those set out in the Priority Subscription Notice, the Company shall not issue or sell any New Shares thereafter without resending the Priority Subscription Notice to the Investors and
the Investors’ exercise of the Right of First Refusal under this Clause 3. 

  

	3.5	 Termination. The Right of First Refusal of each Investor shall be terminated at the time of the
completion of the Qualified Public Offering and delivery. 

  

	4.	 TRANSFER RESTRICTIONS 

 

	4.1	 Sell limit. Each Existing Major Shareholder agrees that no Equity Securities shall be transferred,
directly or indirectly, from the date of this Agreement until the time of completion of the Qualified Public Offering and delivery, except with the prior written consent of each Investor and having complied with the provisions of this Clause 4, that
each Existing Major Shareholder shall cause its Related Parties to comply with this Clause 4. 

  

	4.2	 Preemptive Right. 

 

	 	(a)	 Notice of Transfer. If (i) a Disposing Shareholder intends to Transfer directly or indirectly any of his
Equity Securities to one or more third parties, or (ii) at any time any Equity Securities held by a Disposing Shareholder are involuntarily transferred, the Disposing Shareholder shall give notice in writing (the “Notice of
Transfer”) to the company to whom the Transfer is made and to the Investors. Such Notice of Transfer shall include (A) a description of the Equity Securities to be transferred (the “Sold Shares”), (B) the identity of
the potential transferee, and (C) the consideration for the proposed Transfer and the principal terms and conditions upon which it is based. The price of each Sold Share shall not be lower than the Price Per Share for Investors. The Notice of
Transfer shall prove that the Disposing Shareholder has received a firm offer from the potential assignee and is satisfied in good faith that it may enter into a binding agreement on the Transfer in accordance with the terms of the Notice of
Transfer. The Notice of Transfer shall also include a copy of any written proposal, term sheet or letter of intent or other agreement relating to the proposed Transfer. 

 

	 	(b)	 Exercise of Preemptive Right. 

 

	 	(i)	 Each Investor shall have the right to give written notice (the “Purchase Notice”) to the
Disposing Shareholders within five (5) Working Days (the “Preemptive Period”) of receipt of the Notice of Transfer to give priority to purchase the Sold Shares on the terms and conditions set forth in the Notice of Transfer
(subject to the provisions of Clause 4.1(b)(ii) below) (the “Preemptive Right”). The Purchase Notice shall state the amount of Sold Shares to be purchased by each Investor. 

  
 10 

	 	(ii)	 The number of Sold Shares available for each Investor: Where Investors claim to exercise the Preemptive Right,
the respective purchase proportion shall be determined through consultation. If no agreement can be reached, the Preemptive Right shall be exercised in proportion to the total number of shares held by the investors who claim the Preemptive Right at
the time of transfer, which shall be equal to the total number of shares held by the investors who claim the Preemptive Right at that time. 

  

	 	(iii)	 If an ongoing Transfer arises as a result of enforcement of law or another involuntary transfer (including a
transfer arising from death, divorce, separation or insolvency), the price per share should be the higher of the following: (A) the original purchase price paid by the Disposal Shareholder for the Sold Shares (subject to such adjustments as may
be appropriate in the case of share splits, dividends distribution, mergers and the like), but not less than the nominal value, or (B) the fair market value (not less than the nominal value) of the Sold Shares, as determined by the Board of
Directors, taking into account such factors as the Company’s current income and future prospects and reflecting the current value of the Shares, and determined by the Company within thirty (30) Working Days of receipt of the Notice of
Transfer. If the Disposing Shareholder or the executor of the Disposing Shareholder disagrees with the valuation determined by the Board of Directors, then the Disposing Shareholder or the executor of the disposing shareholder shall have the right
to entrust an independent appraiser agreed by the Company and the Disposing Shareholder or the executor of the Disposing Shareholder to determine the valuation, and the appraiser’s expenses shall be shared equally between the Company and the
Disposing Shareholder or the estate of the Disposing Shareholder. 

  

	4.3	 Co-Sale Rights. If any investor fails to exercise the Preemptive
Right mentioned in the preceding paragraph, within ten (10) Working Days after the expiration of the Preemptive Period (the “Co-Sale Period”), such Investor may give a written notice (the
“Co-Sale Notice”) to the Disposing Shareholder and the Company requiring the Investor’s shares in the Company to be sold to a potential transferee of the Sold Shares (the “Co-Sale Rights”) in accordance with the sale price of the Sold Shares and other terms and conditions set out in the Notice of transfer. Investor’s Sellable Shares = (the percentage of Sold Shares of
Disposing Shareholder to all of their shares * the number of shares held by the investor). If a potential transferee of Sold Shares refuses to purchase any number of shares to be sold by the investor, or the potential transferee fails to complete
the purchase of the shares to be sold by the Investor before or at the same time as the purchase of the Sold Shares is completed, the Disposing Shareholder shall not sell any of the Sold Shares to the potential transferee unless the Disposing
Shareholder completes the purchase of the Investor’s shares to be sold prior to or at the same time as the sale price (not less than the nominal value) and other terms and conditions set out in the Notice of Transfer. 

  
 11 

	4.4	 Not Exercising Rights. If Investors fail to exercise the Preemptive Right under Clause 4.2 and the Co-Sale Right under Clause 4.3, the Disposing Shareholder shall sell any remaining Sold Shares to the third party transferee identified in the Notice of Transfer within ninety (90) days after the expiration of
the Co-Sale Rights Period, on terms and conditions (including the Purchase Price) not favorable to the Purchaser as set forth in the Notice of Transfer. As a condition for the effective Transfer of the Sold
Share, the third party transferee shall provide the Company and all shareholders of the Company with written consent to be bound by and to comply with this Agreement, including but not limited to all provisions of this Clause 4, as if the transferee
were a Disposing Shareholder in this Agreement and to comply with the terms of the transferee under which the Equity Securities are issued. If the Disposing Shareholder fails to complete the sale or disposal of the Sold Shares within ninety
(90) days after the expiration of the Co-Sale Right Period, or the Company proposes to sell the Sold Shares on more favorable terms than those set out in the Notice of Transfer, or the Company proposes to
sell the Sold Shares to a party other than a third party transferee as identified in the Notice of Transfer, the Disposing Shareholders shall not sell any Sold Shares until the Investors have re-exercised
their Preemptive Rights and Co-Sale rights under this Clause 4. Moreover, whether any investor exercises a Preemptive Right or a co-sale right over the Sold Shares of
the Disposing Shareholder shall not adversely affect the subsequent purchase of Equity Securities by the investor from any Disposing Shareholder. Any subsequent Transfer of any Sold Shares proposed by the Disposing Shareholders shall again be
subject to the Preemptive Rights and Co-Sale rights of the Investors and the relevant Disposing Shareholders shall be required to comply with the procedures set out in this Clause 4. 

 

	4.5	 Legend. 

  

	 	(a)	 Each certificate issued to each Existing Major Shareholder representing the Ordinary Share shall endorse the
following legend: 

 “The sale, pledge, mortgage or transfer of the securities represented by this Certificate is
subject to specific restrictions on the transfer under the Shareholders’ Agreement, a copy of which may be obtained by written request to the Secretary of the Company.” 

 

	 	(b)	 The Parties agree that the Company may direct its Transfer agent to impose transfer restrictions on the Shares
represented by the certificates of the legend referred to in Clause 4.5 (a) above for the purpose of enforcing the terms of this Agreement, and the Company agrees to do so forthwith. The legend shall be removed at the termination of the provisions
of this Clause 4. 

  

	4.6	 Transfer of Investor’s Equity. Each Investor shall not be subject to any restrictions on the
Transfer of his/her Equity Securities in the Company (provided that such transfer shall not be made to a competitor of the Company or a transferee associated with the competitor). 

 

	4.7	 Term. This Clause 4 shall terminate at the time of completion of the Qualified Public Offering and
delivery. 

  
 12 

	5.	 TRANSFER AND AMENDMENT 

 

	5.1	 Transfer. When each Investor transfers the shares of the Company he/she holds, all and any rights and
interests relating to such shares may be fully transferred. 

  

	5.2	 Rights of Amendment. Any terms of this Agreement may be amended only with the written consent of each
Existing Major Shareholder and Investors. Any amendment or waiver that becomes effective pursuant to this Clause 5.2 shall be binding upon the Parties hereto and their respective transferees. 

 

	6.	 COMPENSATION 

  

	6.1	 The Founders and the Group Companies shall indemnify, defend and protect Investors, jointly and separately,
against all Losses arising directly or indirectly from, in connection with or incidental to any violation of any representations, warranties, undertakings or agreements made in this Agreement or in any transaction agreement to be signed in this
Agreement. The compensation shall first be borne by each Group Companies. If each Group Company cannot make compensation after its best efforts, the Founders shall perform the compensation obligation. 

 

	7.	 CONFIDENTIALITY AND NON-DISCLOSURE 

 

	7.1	 Confidentiality. Shall be executed in accordance with the Confidentiality Agreement signed between the
Company and Shanghai Zhijun Asset Management Co., Ltd. 

  

	8.	 VOTING RIGHTS, PROTECTIVE CLAUSES AND DIVIDEND RIGHTS. 

 

	8.1	 Voting Rights. Except as otherwise provided in this Agreement, the Articles of Association as defined
below and Applicable Law, any Ordinary Share shall have one vote on any matter of the Company to be resolved by the Shareholders and each Investor shall vote and resolve as a series of Shareholders with each Existing Shareholder. If the proportion
of Equity Securities held by the Shareholders present at the Shareholders’ meeting reaches two thirds (2/3) of the Equity Securities already issued at that time, the resolution made at the shareholders’ meeting shall be valid. Each
Shareholder’s Representative may attend a meeting of the Shareholders through any teleconference or other means of communication available to all Shareholders’ Representatives attending the meeting of the Shareholders. Where a resolution
of the Shareholders’ meeting is made by means of a written resolution without convening a Shareholders’ meeting, such written resolution must be signed by all the Shareholders of the Company for the purpose of validity.

  

	8.2	 Protective Clauses that Require the Approval of Majority Shareholders. In accordance with the
Company’s latest Articles of Association, the following actions of any Group Company require the prior consent of the majority shareholder who holds a total of two-thirds (2/3) of the issued Equity
Securities of the Company: 

  

	 	(a)	 increase or decrease the authorized share capital, issued share capital or registered capital;

  
 13 

	 	(b)	 any Equity Securities, options to purchase Equity Securities, new issues relating to Equity Securities or debt
securities; 

  

	 	(c)	 any liquidation, dissolution, winding-up, recapitalization,
reorganization, consolidation, separation, listing or bankruptcy proceedings; 

  

	 	(d)	 any material change to the Articles of Association or other Organizational Document; 

 

	 	(e)	 the reclassification of any issued Equity Security so that its priority over dividends or assets is higher than
or equal to that of the shares of the Company held by individual Investors. 

  

	8.3	 Corporate Governance. 

 

	 	(a)	 Designation of Directors. The Board of Directors shall include seven (7) voting directors, of whom
Chris Chang Yu shall have the right to appoint and remove five (5) voting directors, Zhangjiang Science Investment shall have the right to appoint and remove one (1) voting director (the “Zhangjiang Science Investment
Director”) and Zhijun Investment shall have the right to appoint and remove one (1) voting director (the “Zhijun Investment Director”, collectively with Zhangjiang Science Investment Director referred to as the
“Investor Director”). There are no qualifications for directors to hold shares. Without the prior written consent of each Investor, the Company shall not increase the number of directors before the next financing round.

  

	 	(b)	 Meetings of the Board of Directors. Meetings of the Board of Directors shall be held at least once every
six (6) months. Each Person may attend a meeting of the Board of Directors by teleconference or other means of communication accessible to all participants. A person attending a meeting of the Board of Directors in that manner shall be deemed
to be attending the meeting in person. 

  

	 	(c)	 Rules for Board Resolutions. The number of directors present at a meeting of the Board of Directors of
the Company shall be three fifths of the total number of directors (i.e. five (5) directors, all directors must be notified fifteen (15) days in advance), and the resolutions made at such meeting of the Board of Directors shall be valid
(the “Number of Effective resolution of Directors”). If the number of directors present in person or by proxy at any meeting of the Board is less than the Number of Effective Resolution of Directors in force for a resolution under
this Clause 8.3(c), the Board shall not pass any resolution on any matter. 

  

	 	(d)	 Corporate Governance of the Group Companies. The Board of Directors of all Group Companies shall be
reconstituted so that each Investor shall have the right to appoint to any Group company the same number of directors as he or she has the right to appoint to the Company, and such directors shall be appointed or removed only in accordance with the
decision of investors who have the right to appoint or remove them. Each Group Company and each Existing Major Shareholder shall cause (a) all corporate conduct of any Group Company to comply with the resolutions of the Board of Directors;
(b) no Group Company shall take any action without the approval of the Board; and (c) the Group Company will act upon the approval of the Board of Directors. 

  
 14 

	 	(e)	 Insurance and Indemnity. The Company shall use its commercially reasonable efforts to insure the
directors of the Board and the directors of any Group Company against the usual directors and officers. The reasonable expenses necessary for the Investor Director to exercise their powers under this Agreement and the Restated Articles of
Association (and any amendments thereto) and Applicable Laws shall be borne by the Company. 

  

	8.4	 Protective Clauses Requiring Unanimous Consent of All Directors. Except for the restrictions set out in
the latest Articles of Association, the following actions of any Group Company shall require the prior and unanimous consent of all directors of the Company: 

  

	 	(a)	 any liquidation, dissolution, reorganization, consolidation, division, listing or bankruptcy proceedings;

  

	 	(b)	 any reduction in share capital, any repurchase or redemption of shares, except for the repurchase of shares
from employees, directors and advisers of any Group Company in accordance with contractual rights due to termination of employment or service; 

  

	 	(c)	 change or cease to engage in any activity within the existing scope of business or principal business of any
Group Company, participate in any industry area that is materially different from the existing business scope or main business activities of any Group Company, approve the participation of any Group Company in any industry area that is materially
different from the existing business plan, and terminate any main business of any Group Company; 

  

	 	(d)	 Approve or amend the Company’s Overall Employee Share Option Plan or Rules for Issuance and the Overall
Share Option Plan for senior managers; 

  

	 	(e)	 amendment or alteration of the rights, priorities, privileges or powers of each Investor in the shares of the
Company, or of any restrictions imposed for his/her benefit; 

  

	 	(f)	 any act of authorizing, creating or issuing any class or series of securities having priority over or equal to
the shares of the Company held by each Investor; 

  

	 	(g)	 the reclassification of any issued shares so that they have priority over dividends or assets over or equal to
that of the shares of the company held by individual Investors; 

  

	 	(h)	 sell, lease, Transfer or otherwise dispose of all or substantially all of the assets of the Group Company.

  
 15 

	8.5	 Protective Clauses to Be Adopted by the Majority of Directors. Except for the restrictions set out in
the Articles of Association, the following actions of any Group Company require prior consent of at least four-sevenths or above of the all Directors of the Company: 

 

	 	(a)	 the formulation of the operating policies and investment plans of any Group Company; 

 

	 	(b)	 Approval or any amendment of the annual business plan, budget programme or final accounts programme;

  

	 	(c)	 Approval or any amendment of the profit distribution plan and the loss recovery plan; 

 

	 	(d)	 Approval or any amendment of a material financing proposal; 

 

	 	(e)	 Acquire, sell, lease, Transfer or otherwise dispose of assets that exceed 10% of the net assets of each Group
Company; 

  

	 	(f)	 Foreign investment disposal exceeding 10% of the net assets of each Group Company; 

 

	 	(g)	 Related Party transactions (the directors of Related Parties need to evade); 

 

	 	(h)	 Expenditure in excess of RMB1,000,000 for any single transaction or series of similar transactions, which shall
be increased by 10% every 12 months from the date this Agreement is signed into force; 

  

	 	(i)	 Formulate a listing plan; 

 

	 	(j)	 Appointment and removal and changes of auditors or any material change in the accounting or financial system;

  

	 	(k)	 Foreign investment behavior, whether it is equity investment or debt investment; 

 

	 	(l)	 External guarantees; 

 

	 	(m)	 A single transaction exceeding RMB1,500,000 and a net transaction exceeding RMB6,000,000 among the Group
Companies; And 

  

	 	(n)	 Approval or amendment of the overall incentive plan for employee equity other than senior management.

  

	 	(o)	 increase the authorized share capital, issued share capital or registered capital; 

 

	 	(p)	 Investment plans for the construction project of any Group Company. 

 

	8.6	 Dividend Rights. Investors have the right to participate in any dividends and other distributions of the
Company in proportion to their Equity Securities held in the Company and other Shareholders. 

  
 16 

	9.	 ANTI-DILUTION 

 

	9.1	 If the Company issues any New Shares or any additional capital, except for the executive employee incentive
plan approved by the Board of Directors, and the unit price of such New Shares is lower than the Price Per Share for Investors, as an anti-dilution protection measure, the Investor shall have the right to further acquire the shares issued by the
Company at zero consideration or at the lowest consideration permitted by other laws to ensure that the Investor’s rights and interests in the Company are not diluted. 

 

	10.	 OTHER CLAUSES 

 

	10.1	 If the investment cost of Investors to the Group Company is inconsistent with the actual investment cost, where
the Investors are required to bear additional tax costs due to the inconsistent tax basis in the future reorganization or realization of investment in the Group Company, the Company and the Founders shall take all necessary measures to ensure that
the Investors shall not incur any additional costs or Losses as a result thereof. Such measures shall include, but are not limited to: 1. Ensuring that Investors shall not bear such tax costs and other Losses; 2. Ensuring that Investors shall
receive after-tax income calculated on the basis of actual investment costs (including, but not limited to, raising the next valuation, etc.). If the Company and the Founders fail to achieve the effect agreed
in the foregoing terms and conditions through all efforts, the Parties concerned shall, with the written consent of the Investors, negotiate and resolve the matter separately under the principles of fairness and impartiality. In the event that the
Parties fail to resolve the matter through negotiation within thirty (30) calendar days, the Company and the Founders shall be jointly and severally liable for all costs and Losses borne by the Investors. 

 

	10.2	 The Company promises to Zhijun Investment that, except for the circumstances in which the Company has disclosed
to Zhijun Investment, there is no superiority over the undertaking in relation to the rights under this Agreement in any agreement between the Company and other natural persons and institutions that subscribed for the shares of the Company before
the signing of this Agreement. Otherwise, Zhijun Investment shall be entitled to equal rights in accordance with these terms. 

  

	10.3	 Registration Rights. When any Investor requests, each Group Company, Existing Major Shareholders shall
cause the Group Company planning to make a public offering to grant the Investor (to the reasonable satisfaction of the Investor) the right to register with the Securities and Exchange Commission all securities held by the Investor (including, but
not limited to, three (3) times of demand registration and an unlimited number of “piggyback” and F-3/S-3 Form registration rights (or any
subsequent registration under the Securities Act)), or an equivalent or similar right to register any issue in any other jurisdiction of securities of any Group Company in respect of which the Group Company undertakes to make a public offering or to
list such securities on a recognized stock exchange. 

  
 17 

	11.	 GENERAL CLAUSES 

 

	11.1	 Binding Force; Transfer. Subject to Clause 5.1, this Agreement shall be binding upon and beneficial to
the heirs, successors, executors and administrators of the Parties hereto, as well as the Transferee. However, this Agreement shall not be transferred by any party to this Agreement (other than Investors) without the prior written consent of the
respective Investors. This Agreement and the rights and obligations hereunder may be transferred by any Investor to any Person without the prior written consent of the other Parties to this Agreement, provided that such Person has signed a contract
of compliance and consented to be bound by this Agreement. 

  

	11.2	 Applicable Law. This Agreement shall be governed by and construed in all respects in accordance with the
laws of Hong Kong. 

  

	11.3	 Dispute Resolution. 

 

	 	(a)	 Any dispute, contradiction or claim arising out of or relating to this Agreement, or the interpretation, breach
of contract, termination or validity of this Agreement (each referred to as a “Dispute”) shall be settled first through consultation by the Parties to the Dispute. Such consultation shall commence immediately upon written notice of
any request for consultations by either Party to the Dispute. 

  

	 	(b)	 If the Dispute is not resolved within fifteen (15) days from the date of the aforesaid notice, either
Party to the Dispute may submit it to arbitration by giving notice to the other Parties to the Dispute (the “Notice of Arbitration”). 

  

	 	(c)	 The arbitration shall be submitted to the Shanghai Arbitration Commission for final award.

  

	 	(d)	 Either Party to the arbitration shall cooperate with the other Parties to the arbitration and, subject to its
obligation of confidentiality, such party shall fully disclose and allow full access to all information and documents required by the other Party in connection with the arbitration proceedings. 

 

	 	(e)	 Unless otherwise awarded by the arbitral tribunal, the costs of the arbitration shall be borne by the losing
Party. 

  

	 	(f)	 In the event of a Dispute and the arbitration thereof, the Parties shall continue to perform their respective
obligations and shall be entitled to exercise their rights under this Agreement, except in the case of such Dispute. 

  

	 	(g)	 The award of the arbitral tribunal shall be final and binding on the Parties, and the prevailing Party shall
apply to the jurisdictional court for enforcement of the award. 

  

	 	(h)	 In the course of the arbitral tribunal’s hearing of the Dispute, this Agreement shall continue to be
performed except for the part of the Dispute that is in it. 

  

	11.4	 Complete Agreement. Except as disclosed by the Company to Zhijun Investment prior to the signing of this
Agreement, this Agreement, the Subscription Agreement and any other Transaction Agreement contemplated by this Agreement and the annexes and schedules hereto constitute the entire understanding and agreement between the Parties and supersede all
prior written or oral understandings or agreements with respect to the subject matter hereof. 

  
 18 

	11.5	 Except as otherwise provided herein, all notices, requests, waivers or other communications made pursuant to
this Agreement shall be in writing and shall be deemed to have been duly served at the time of delivery if (a) delivered personally at the address set forth in Appendix A to this Agreement; (b) by facsimile transmission at the
number listed in Appendix A to this Agreement, upon receipt of confirmation of facsimile correctness (and a record of receipt of a written reply); (c) by airmail or registered mail (requiring a receipt, postage prepaid, address as set out in
Appendix A to this Agreement and with a sign-off record), five (5) Working Days after the date of delivery; (d) by overnight courier service (postage prepaid, sent at the address set forth in
Appendix A to this Agreement and guaranteed to be delivered on the following Working Day and with a sign-off record), three (3) Working Days after the date of delivery, provided that the sending
Party obtains a confirmation of delivery from the delivery agency; or (e) if the e-mail is sent in accordance with the e-mail address listed in Appendix A to
this Agreement, at the time the e-mail is normally sent (and there is a record of receipt of the e-mail reply). 

If communications under this Agreement are transmitted by facsimile, the sending Party shall immediately confirm each communication faxed
pursuant to this Agreement by telephone to the received Party, but the failure to do so shall not affect the validity of such communications. For the purposes of this Clause 11.5, either Party may change or supplement the address set out in
Appendix A or designate additional addresses by giving written notice to the other Parties in the manner described above. 
  

	11.6	 Delay or Omission. Either Party delays or fails to exercise the rights, powers or relieves conferred
upon it by the other Party for breach or non-performance of this Agreement, shall not prejudice the right, powers or relief of that Party, nor shall it be deemed to be a waiver of or acquiescence in the breach
or non-performance or any subsequent similar breach or non-performance, nor shall it be deemed to be a waiver of any other breach or
non-performance occurring before or after that date. A waiver, permission, consent, or approval of a breach or non-performance of any of the nature or characteristics of
this Agreement or waiver of any of the terms or conditions of this Agreement must be made in writing and shall be valid only to the extent specified in such writing. Any relief provided to either Party under this Agreement, by law or otherwise,
shall be cumulative but not optional. 

  

	11.7	 Severability. If any provision of this Agreement is invalid or unenforceable, it shall be construed so
far as is practicable to enable it to be executed and to enable the transaction under this Agreement to be completed on substantially the same terms as previously stated. If there is no workable interpretation for the retention of this clause, it
shall be severed from the remainder of this Agreement, which shall remain in full force and effect unless the severed clause is essential to the rights and interests intended by the Parties. In such circumstances, the Parties shall use their best
endeavors to negotiate in good faith an effective and enforceable alternative Clause or Agreement in order to achieve to the fullest extent on the intentions of the Parties at the time of entering into this Agreement. 

 

	11.8	 Shareholder’s Agreement Prevails. In the event of any inconsistency between the
clauses of this Agreement and the Articles of Association, the clauses of this Agreement shall prevail for the sole benefit of the Shareholders of the Company. Upon the discovery of such inconsistencies, the Parties agree to take all necessary or
desirable measures for consultation to eliminate such inconsistencies to the fullest extent permitted by Applicable Law. 

  
 19 

	11.9	 Come into Force. This Agreement shall come into force on the date of delivery upon signature by the
Parties. 

  

	11.10	 Copy. This Agreement may be signed on any number of texts, all of which are originals, but all of which
together constitute one document. 

  
 20 

 [No text below] 

In view of this, the Parties hereto have caused their duly authorized representatives to sign this Agreement as of the date on the head of the
text. Place of execution of this Agreement: Shanghai, China. 
 Group Companies: 
  

	
	AnPac Bio-Medical Science Co., Ltd.
	
	Signature: /s/ Chris Chang Yu                    
	Name: Chris Chang Yu
	Title: Chairman
	
	Zhejiang AnPac Bio-Medical Science Co., Ltd. (Seal)
	
	Signature: /s/ Chris Chang Yu                    
	Name: Chris Chang Yu
	Title: Legal Representative
	
	Changhe Bio-Medical Science (Yangzhou) Co., Ltd. (Seal)
	
	Signature: /s/ Chris Chang Yu                    
	Name: Chris Chang Yu
	Title: Legal Representative

  
 21 

 In view of this, the Parties hereto have caused their duly authorized representatives to
sign this Agreement as of the date on the head of the text. Place of execution of this Agreement: Shanghai, China. 
 Group Companies: 

 

	
	Changwei System Technology (Shanghai) Co., Ltd. (Seal)
	
	Signature: /s/ Chris Chang Yu                    
	Name: Chris Chang Yu
	Title: Legal Representative
	
	AnPac Bio-Medical Science (Shanghai) Co., Ltd. (Seal)
	
	Signature: /s/ Chris Chang Yu                    
	Name: Chris Chang Yu
	Title: Legal Representative
	
	Shanghai Xinshenpai Technology Co., Ltd. (Seal)
	
	Signature: /s/ Chris Chang Yu                    
	Name: Chris Chang Yu
	Title: Legal Representative

  
 22 

 In view of this, the Parties hereto have caused their duly authorized representatives to
sign this Agreement as of the date on the head of the text. Place of execution of this Agreement: Shanghai, China. 
 Group Companies: 

 

	
	Lishui AnPac Medical Laboratory Co., Ltd.
	
	Signature: /s/ Chris Chang Yu                    
	Name: Chris Chang Yu
	Title: Legal Representative
	
	Chengdu Lipaishen Bio-Medical Science Co., Ltd. (Seal)
	
	Signature: /s/ Xuedong Du                    
	Name: Xuedong Du
	Title: Legal Representative
	
	ANPAC TECHNOLOGY USA CO., LTD.
	
	Signature: /s/ Chris Chang Yu                    
	Name: Chris Chang Yu
	Title: Legal Representative

  
 23 

 In view of this, the Parties hereto have caused their duly authorized representatives to
sign this Agreement as of the date on the head of the text. Place of execution of this Agreement: Shanghai, China. 
 Existing Major Shareholders: 

 

			
	Chris Chang Yu
		
	Signature:	 	 /s/ Chris Chang Yu

		
	Lin Yu	 	
		
	Signature:	 	 /s/ Lin Yu

	
	CRS Holdings Inc.
		
	Signature:	 	 /s/ Chris Chang Yu

	Name: Chris Chang Yu
	Title: President

  
 24 

 In view of this, the Parties hereto have caused their duly authorized representatives to
sign this Agreement as of the date on the head of the text. Place of execution of this Agreement: Shanghai, China. 
 Investors: 

 

			
	Zhangjiang GU KE Company Limited
		
	Signature:	 	 /s/ Guo Fuyun

	Name: Guo Fuyun
	Title: Director

  
 25 

 In view of this, the Parties hereto have caused their duly authorized representatives to
sign this Agreement as of the date on the head of the text. Place of execution of this Agreement: Shanghai, China. 
 Investors: 

Jiaxing Zhijun Sihang Investment Partnership (Limited Partnership) 
  

			
	Signature:	 	 /s/ Yu Jinjie

			
	Name:	 	Yu Jinjie

			
	Title:	 	Representative of Executive Partner

  
 26 

 Appendix A 

Notice Address 
 For the purposes of the
Notice Clauses set out in this Agreement, the initial addresses of the Parties are as follows: 
  

	
	To Existing Major Shareholders:
	
	Address:
	Zip code:
	Email:
	Addressee:
	
	To any Group Companies:
	
	Address:
	Zip code:
	E-mail:
	Addressee:
	
	To Investors:
	
	Zhangjiang GU KE Company Limited
	
	Address:
	Zip code:
	E-mail:
	Addressee:
	
	Jiaxing Zhijun Sihang Investment Partnership (Limited Partnership)
	
	Address:
	Fax:
	E-mail:
	Addressee:

  
 27EX-4.5

 Exhibit 4.5 

August 17, 2017 

Shareholders Agreement 
  

 
  

AnPac Bio-Medical Science Co., Ltd. 

 
  

A limited liability company incorporated in the British Virgin Islands 

 Shareholders Agreement 

The Shareholders Agreement (this “Agreement”) is signed by the following Parties on August 17, 2017: 

 

	(1)	 AnPac Bio-Medical Science Co., Ltd., a limited liability company
legally established and validly existing in the British Virgin Islands, with its registered address at SHRM Trustees (BVI) Limited of Trinity Chambers, P.O. Box 4301, Road Town, Tortola, British Virgin Islands (the “Company”);

  

	(2)	 Dr. Chris Chang Yu, U.S. Citizen, ID number [    ];

  

	(3)	 CRS Holdings INC., a limited liability company legally established and validly existing in the British
Virgin Islands, with its registered address at SHRM Trustees (BVI) Limited of Trinity Chambers, P.O. Box 4301, Road Town, Tortola, British Virgin Islands (“CRS Company”); 

 

	(4)	 Ms. Lin Yu, Chinese citizen, ID number [    ];

  

	(5)	 Zhejiang AnPac Bio-Medical Science Co., Ltd., a limited
liability company legally established and validly existing in China, with its registered address at Room 108, No.131 Nanshan Yuanyuan Middle Road, Bihu Town, Liandu District, Lishui City, Zhejiang Province (“Lishui Company”);

  

	(6)	 Changhe Bio-Medical Science (Yangzhou) Co., Ltd., a limited
liability company legally established and validly existing in China, with its registered address at 3rd Floor, Building 9, Jiangsu Information Service Industry Base (Yangzhou) (“Yangzhou Company”); 

 

	(7)	 Changwei System Technology (Shanghai) Co., Ltd., a limited liability company legally established and
validly existing in China, with its registered address at Room 316, No. 105 Sinan Road, Huangpu District, Shanghai (“Changwei Company”); 

 

	(8)	 AnPac Bio-Medical Science (Shanghai) Co., Ltd., a limited
liability company legally established and validly existing in China, with its registered address at Room 301-346, Building 1, No. 400, Fangchun Road, Zhangjiang
Hi-Tech Park, Shanghai (“AnPac Shanghai Company”); 

  

	(9)	 Shanghai Xinshenpai Science Co., Ltd., a limited liability company legally established and validly
existing in China, with its registered address at Room 316, No. 105 Sinan Road, Huangpu District, Shanghai (“Xinshenpai Company”); and 

  

	(10)	 Lishui AnPac Medical Laboratory Co., Ltd., a medical institution legally established and validly
existing in China, with its registered address at No. 801, Bixing Street, Bihu Town, Liandu District, Lishui City, Zhejiang Province (“Medical Laboratory”); and 

 

	(11)	 Chengdu Lipaishen Bio-Medical Science Co., Ltd., a limited
liability company legally established and validly existing in China, with its registered address at Building 1, No. 9, Shaocheng Road, Qingyang District, Chengdu City (“Chengdu Company”);and 

  
 1 

	(12)	 ANPAC TECHNOLOGY USA CO., LTD., a limited liability company legally established and validly existing in
the United States, with its registered address at 1209 ORANGE STATE, WILMINGTON DE 19801 (“AnPac U.S.”); 

  

	(13)	 EMPOWER FUND I, L.P., a limited liability company legally established and validly existing in the Cayman
Islands, with its registered address at 94 Solaris Avenue, Camana Bay, P.O. Box 1348, Grand Cayman, KY1-1108, Cayman Islands (“EMPOWER Investment”). 

In this Agreement, Chris Chang Yu and CRS Company are hereinafter referred to individually as the “Founder” and collectively as the
“Founders”; Founders and Ms Lin Yu are hereinafter referred to individually as the “Existing Major Shareholder” and collectively as the “Existing Major Shareholders”; EMPOWER Investment is
hereinafter referred to individually as “Investor”; Existing Major Shareholders and other Shareholders of the Company shall be collectively referred to as the “Existing Shareholders”; Lishui Company, Yangzhou
Company, Changwei Company, AnPac Shanghai Company, Xinshenpai Company, Medical Laboratory, Chengdu Company and AnPac U.S. are hereinafter referred to individually as the “Domestic And Foreign Company” and collectively as the
“Domestic And Foreign Companies”; The Company and Domestic And Foreign Companies and all other direct or indirect, current or future subsidiaries of the above companies are referred to individually as “Group
Company” and collectively as the “Group Companies”; The Parties to this Agreement are referred to collectively as the “Parties” and individually as the “Party”. 

Preface 
 Whereas, the Company and EMPOWER
Investment signed a Share Subscription Agreement (the “Subscription Agreement”) on August 17, 2017; 
 For the purpose of agreeing on
the shareholder rights of EMPOWER Investment, the Parties hereby agree as follows: 
  

	1.	 DEFINITION 

  

	1.1	 Definition. Unless otherwise defined in this Agreement, the extrabold terms in this Agreement shall have
the following meanings: 

  

	 “AnPac Shanghai Company” 
	It shall have the meaning of the preceding provisions. 

  

	 “Applicable Law” 
	Refers to any Person, suitable for the Person or any of its assets or business, whether it be on or after the date of this agreement valid and amended from time to time or any of the constitution, treaty, statute, law, statute, decree, norm,
regulation, judgment, general law rule, order, edict, adjudication, prohibition, Government Approval, approval, grant, franchise, license, consent, order, requirement, or any other government restriction of any Government Agency or any similar form
of decree, or any decision made by it, or the interpretation and implementation of any of the foregoing. 

  
 2 

	 “Board of Directors” 
	Refers to the board of directors of the Company. 

  

	 “Changwei Company” 
	It shall have the meaning of the preceding provisions. 

  

	 “China” 
	Refers to the People’s Republic of China, but for the purposes of this Agreement, it does not include Hong Kong, Macao Special Administrative Region and Taiwan. 

 

	 “Company” 
	It shall have the meaning of the preceding provisions. 

  

	 “Confidential Information” 
	It shall have the meaning set forth in Clause 7.1. 

  

	 “Contracts” 
	Refers to any agreement, arrangement, commitment, covenant, franchise, indemnity, contract, instrument, lease, license, permission or binding memorandum of understanding (whether in writing or not). 

 

	 “Control” 
	(Including the relevant meanings for “controlling”, “controlled” and “jointly controlled”) in the case of any person, refers to the right of any Person to directly or indirectly guide the
management or policy of that Person (related to operational control, financial control or other control) whether through securities with voting rights or through contracts or otherwise. 

 

	 “Disposing Shareholder” 
	Refers to any Existing Major Shareholder or assignee of his/her Equity Securities. 

  

	 “Dispute” 
	It shall have the meaning set forth in Clause 10.2(a). 

  

	 “EMPOWER Price Per Share for EMPOWER Investment” 
	Refers to the price obtained by the subscription price divided by the number of the subscription shares, i.e. US$866.55. 

  

	 “Equity Securities” 
	Refers to all Ordinary Shares or securities convertible or exchangeable into Ordinary Shares of the Company. 

  

	 “Existing Major Shareholder” and “Existing Major Shareholders” 
	It shall have the meaning of the preceding provisions. 

  

	 “Existing Shareholders” 
	It shall have the meaning of the preceding provisions. 

  
 3 

	 “Founder” and “Founders” 
	It shall have the meaning of the preceding provisions. 

  

	 “Government Agency” 
	Refers to any government or its political branches, whether at the federal, central, state, provincial, municipal or local levels, regardless of administrative, legislative or judicial nature, including any representative office, authority,
council, bureau, committee, court, department or other organ. 

  

	 “Government Approval” 
	Refers to any consent, approval, authorization, exemption, permit, grant, franchise, allowance, permission, exemption or order of a Government Agency, and registration, certification, declaration, filing, reporting or notification to a
Government Agency. 

  

	 “Group Company” and “Group Companies” 
	They shall have the meaning of the preceding provisions. 

  

	 “Hong Kong” 
	Refers to the Hong Kong Special Administrative Region of China. 

  

	 “Information Right” 
	It shall have the meaning set forth in Clause 2.1(e). 

  

	 “Inspection Right” 
	It shall have the meaning set forth in Clause 2.2. 

  

	 “Investor” and “Investors” 
	It shall have the meaning of the preceding provisions. 

  

	 “Knowledge” 
	When referring to a Person’s “knowledge”, it refers to the actual knowledge of the Person, and the knowledge should be known to the Person as a prudent business Person after proper consultation and due diligence in managing
his/her business. These investigations include appropriate consultation with the management, directors, key employees and professional consultants (including lawyers, accountants and consultants) of the Person and his/her Related Parties.

  

	 “Lishui Company” 
	It shall have the meaning of the preceding provisions. 

  

	 “Loss” 
	Refers to all direct or indirect losses, liabilities, damages, deficiencies, value impairments, litigation, liabilities, duties, benefits, interests, fines, fees, judgments or settlements of any nature or kind, including all related costs and
expenses, including but not limited to reasonable attorney fees and expenses of any kind or nature, legal fees, settlement fees and investigation costs, whether legal or in an equity law, known or unknown, foreseeable or unforeseen.

  
 4 

	 “Material Adverse Effects” 
	Refers to the material adverse effects of a particular Person’s condition (financial or other conditions), his/her associated assets, operating results or prospects, or business (currently or intended to be carried out). 

 

	 “New Shares” 
	It shall have the meaning set forth in Clause 3.2. 

  

	 “Notice of Exercising Right of First Refusal” 
	It shall have the meaning set forth in Clause 3.3. 

  

	 “Notice of Transfer” 
	It shall have the meaning set forth in Clause 4.2(a). 

  

	 “Ordinary Shareholder” 
	Refers to a holder of ordinary shares. 

  

	 “Ordinary Shares” 
	Refers to the Company’s ordinary shares, with a par value of US$1.00 each. 

  

	 “Organizational Document” 
	Refers to, in relation to any Person, a certificate of registration, memorandum of association, articles of association, joint venture agreement, shareholders’ agreement or similar organizational document of such Person. 

 

	 “Party” and “Parties” 
	Shall have the meanings set forth in the preceding provisions, respectively. 

  

	 “Persons” 
	Shall be construed as broadly as possible and shall include individuals, partnerships (including limited liability partnerships), companies, associated companies, joint stock companies, limited liability companies, trusts, joint ventures
(including Sino-foreign joint ventures and Sino-foreign cooperative ventures), non-corporate organizations and Government Agencies. 

 

	 “Preemptive Period” 
	It shall have the meaning set forth in Clause 4.2(b)(i). 

  

	 “Preemptive Right” 
	It shall have the meaning set forth in Clause 4.2(b)(i). 

  

	 “Preface” 
	Refers to the preface of this Agreement. 

  

	 “Price Per Share for Investor” 
	Refers to the Price Per Share of EMPOWER Investment. 

  

	 “Priority Subscription Notice” 
	It shall have the meaning set forth in Clause 3.3(a). 

  

	 “Priority Subscription Period” 
	It shall have the meaning set forth in Clause 3.3(a). 

  
 5 

	 “Purchase Notice” 
	It shall have the meaning set forth in Clause 4.2(b)(i). 

  

	 “Qualified Public Offering” 
	The Company or any other Group Company shall be listed on a stock exchange in China, Hong Kong or other internationally recognized stock exchange and shall publicly issue Ordinary Shares or shares of the Group Company in accordance with the
securities trading laws and regulations of the applicable jurisdiction. 

  

	 “Related Parties” 
	In the case of a specific Person, it refers to (a) when he/she is a natural person, his/her spouse and his/her immediate family members (whether blood relatives or adoption) or any trust established and maintained solely for the benefit of
the person, his/her spouse and/or such immediate family members; and (b) when it is any person, directly or indirectly through one or more media, controlling the specific Person, being controlled by the specific Person or being controlled
jointly with the specific Person. 

  

	 “Ren Min Bi” or “RMB” 
	Refers to the legal currency of China. 

  

	 “Right of First Refusal” 
	It shall have the meaning set forth in Clause 3.1. 

  

	 “Subsidiary” 
	Refers to in relation to the specific Person, any other non-natural Person controlled by that specific Person. 

  

	 “Senior Executives” 
	Refers to the CEO, CFO, COO of each Group Company and the Deputy General Manager or above. 

  

	 “Shareholders” 
	Refers to any Person who holds Equity Securities. 

  

	 “Sold Shares” 
	It shall have the meaning set forth in Clause 4.2(a). 

  

	 “This Agreement” 
	It shall have the meaning of the preceding provisions. 

  

	 “Transfer” 
	Refers to the transfer, sale, guarantee, encumbrance, mortgage, pledge, donation or other disposition of any or all of the shares of a particular Person, whether voluntary or involuntary (including but not limited to those arising from divorce,
separation, bankruptcy or other proceedings, or death) or by operation of law. 

  

	 “US$” 
	Refers to the legal currency of the United States. 

  

	 “Working Day” 
	Refers to any day on which banks in the British Virgin Islands and China normally operate (except Saturdays and Sundays and public holidays in the British Virgin Islands or China). 

  
 6 

	 “Xinshenpai Company” 
	It shall have the meaning of the preceding provisions. 

  

	 “Yangzhou Company” 
	It shall have the meaning of the preceding provisions. 

  

	1.2	 Interpretation. For all purposes of this Agreement, except as expressly provided herein, (a) The
terms defined in the Clause 1.1 shall have the meanings ascribed to them in this Clause 1.1 and shall include the plural and the singular, (b) All accounting terms not otherwise defined in this Agreement shall have the meaning given by the
Chinese Accounting Standards, (c) All designated “Clauses” and “Sub-Clauses” referenced in this Agreement shall mean the Clauses and
Sub-Clauses identified in the Main Body of this Agreement, (d) A gender or neutral pronoun shall include other appropriate forms of the pronoun, (e) The terms “in this Agreement”,
“of this Agreement” and “under this Agreement” and other terms of similar meaning refer to this Agreement as a whole and not designate any particular clause or sub-clause,
(f) Unless otherwise expressly stated, all appendices specified by reference to this Agreement refer to appendices to this Agreement, (g) The term “including” and other similar words shall be deemed to be immediately
followed by “but not limited to”, whether or not they are actually immediately followed by such words or words of similar meaning, (h) The headings of the terms of this Agreement are for identification and reference only and
shall not be used to interpret this Agreement, (i) Any “Party” or any other Person referred to in this Agreement shall be construed as including successors to his/her rights, his/her permitted successors and permitted
assignees, and (j) Any agreement or instrument referred to in this Agreement shall include its amended or substituted text. This Agreement shall be interpreted literally. 

 

	2.	 INFORMATION RIGHT; INSPECTION RIGHT 

 

	2.1	 Information Right. The Company warrants and agrees that, as of the date of this Agreement, it will
deliver to each Investor: 

  

	 	(a)	 The annual consolidated financial statements of each Group Company prepared in accordance with the Chinese
Accounting Standards and other applicable local accounting terms and rules and audited by an accounting firm as agreed by the Company and the Investors shall be delivered within one hundred and twenty (120) days after the end of each fiscal
year; 

  

	 	(b)	 The unaudited quarterly consolidated financial and management statements of Group Companies prepared in
accordance with Chinese accounting standards and other applicable local accounting terms and rules shall be delivered within twenty-eight (28) days after the end of six months; 

 

	 	(c)	 An annual business plan and monthly budget for each Group Company for the following fiscal year shall be
delivered within thirty (30) days prior to the end of each fiscal year; 

  

	 	(d)	 Notice of all litigations, prosecutions, claims, judicial proceedings, investigations, inquiries or incidents
that may have a Material Adverse Effect on any Group Company or any of its Related Parties and their ownership of or rights in their respective businesses, real property, assets or property; and 

  
 7 

	 	(e)	 Other information reasonably requested to be delivered by each Investor upon written request by them
(collectively referred to as the “Information Right”). 

  

	 	(f)	 All financial statements to be provided to each Investor in accordance with this Clause 2.1 shall include
income statements, balance sheets and cash flow statements for the relevant periods and for the current fiscal year prepared in accordance with the Chinese Accounting Standards and other applicable local accounting terms and rules.

  

	2.2	 Inspection Right. Each Group Company further warrants and agrees that, as of the date of this Agreement,
each Investor and his or her authorized representative shall have the right (a) to inspect, extract and photocopy the facilities, records and books of account of the Group Company under normal working hours and reasonable and without prejudice
to the normal operation of the Group Company after reasonable prior notice to the Group Company concerned, and (b) to discuss the business, operation and conditions of any Group Company with their respective directors, officers, employees,
accountants, legal advisers and investment banks, without prejudice to the normal operation of the Group Company (the “Inspection Right”). Each Group Company will provide and cause its subsidiaries to provide to each Investor and
his or her authorized representative such information as each Investor may reasonably require from time to time. Each Group Company shall provide all reasonable support to effectively assist in such investigations. Any Investor shall have the right
to require the Group Company to be notified 30 days in advance and to be audited by an accounting firm approved by such Investor, but not more than once a year, at the expense of the Investor, provided that the Investor does not interfere with the
normal operation of the Group Company. 

  

	2.3	 Termination of Rights. The Information Right and the Inspection Right shall be terminated at the time of
the completion of the Qualified Public Offering. 

  

	3.	 RIGHT OF FIRST REFUSAL 

 

	3.1	 Overview. Each Investor shall have priority to purchase all (or any part thereof) of any New Shares
issued by the Company from time to time after the date of this Agreement (the “Right of First Refusal”). 

  

	3.2	 New Share. “New Share” refers to any Equity Securities of the Company (whether or not
it is now an authorized share capital) and rights, options or warrants of any type of securities that may be purchased or converted or exchanged for Equity Securities of the Company. While the term “New Share” shall not include:

  

	 	(a)	 any Ordinary Shares sold or issued under the Subscription Agreement; 

 

	 	(b)	 any securities (including any repurchased shares) issued under the Employee Option Scheme of the Company to
officers, directors, employees and advisers of any Group Company; 

  

	 	(c)	 any securities issued in a Qualified Public Offering; 

 

	 	(d)	 any securities issued as a result of any share splitting or dividend distribution, recapitalization or similar
transaction subject to a pro rata adjustment; and 

  
 8 

	 	(e)	 any securities issued for the purpose of the acquisition in good faith of another company or entity or other
reorganization activity by the Company through merger, consolidation, purchase of all or substantially all of its assets (the relevant conditions of which shall be approved by the Board of Directors). 

 

	3.3	 Procedure. 

  

	 	(a)	 Priority Subscription Notice. If the Company plans to issue New Shares (whether through a single
transaction or a series of related transactions), it shall give each Investor a written notice of its intention to issue such New Shares (the “Priority Subscription Notice”) describing the number, type, price of the New Shares and
the general terms and conditions under which the Company intends to issue such New Shares. Each Investor may, within five (5) Working Days (the “Priority Subscription Period”) from the date of receipt of the Priority
Subscription Notice, agree in writing to purchase the amount of New Shares to be issued at the prices and terms and conditions set out in the Priority Subscription Notice by giving a written notice to the Company (the “Notice of Exercising
Right of First Refusal”) stating the number of New Shares to be purchased. If any investor fails to give a Notice of Exercising Right of First Refusal during the Priority Subscription Period, such Investor shall be deemed to have waived his
Right of First Refusal. The Board of Directors of the Company shall not pass any resolution enabling the Company to issue any New Shares under the Right of First Refusal to any third person that have not been exercised or waived by the Investors in
accordance with the provisions of this Clause 3. The maximum amount of New Shares that any investor is entitled to subscribe for is: New Shares x (the number of Ordinary Shares held by the Investor at the time of the Company’s Priority
Subscription Notice ÷ the sum of all Ordinary Shares issued at the time of the Company’s Priority Subscription Notice). 

  

	3.4	 Failure to Exercise. Upon expiration of the Priority Subscription Period, and in the case that the New
Shares are not fully subscribed by each Investor through the Right of First Refusal, the Company shall, within ninety (90) days after the expiration of the Priority Subscription Period, sell the New Shares described in the Priority Subscription
Notice (in respect of the unexercised portion of the Right of First Refusal) at a price equal to or higher than the price stated in the Priority Subscription Notice, or for non-price terms, on terms no more
favorable than those set forth in the Priority Subscription Notice. If the Company fails to complete the issue and sale of the New Shares within ninety (90) days after the expiration of the Priority Subscription Period, or the Company intends
to issue and sell the New Shares on terms more favorable than those set out in the Priority Subscription Notice, the Company shall not issue or sell any New Shares thereafter without resending the Priority Subscription Notice to the Investors and
the Investors’ exercise of the Right of First Refusal under this Clause 3. 

  

	3.5	 Termination. The Right of First Refusal of each Investor shall be terminated at the time of the
completion of the Qualified Public Offering and delivery. 

  

	4.	 TRANSFER RESTRICTIONS 

 

	4.1	 Preemptive Right. 

  
 9 

	 	(a)	 Notice of Transfer. If (i) a Disposing Shareholder intends to Transfer directly or indirectly any of his
Equity Securities to one or more third parties, or (ii) at any time any Equity Securities held by a Disposing Shareholder are involuntarily transferred, the Disposing Shareholder shall give notice in writing (the “Notice of
Transfer”) to the company to whom the Transfer is made and to the Investors. Such Notice of Transfer shall include (A) a description of the Equity Securities to be transferred (the “Sold Shares”), (B) the identity of
the potential transferee, and (C) the consideration for the proposed Transfer and the principal terms and conditions upon which it is based. The price of each Sold Share shall not be lower than the Price Per Share for Investors. The Notice of
Transfer shall prove that the Disposing Shareholder has received a firm offer from the potential assignee and is satisfied in good faith that it may enter into a binding agreement on the Transfer in accordance with the terms of the Notice of
Transfer. The Notice of Transfer shall also include a copy of any written proposal, term sheet or letter of intent or other agreement relating to the proposed Transfer. 

 

	 	(b)	 Exercise of Preemptive Right. 

 

	 	(i)	 Each Investor shall have the right to give written notice (the “Purchase Notice”) to the
Disposing Shareholders within five (5) Working Days (the “Preemptive Period”) of receipt of the Notice of Transfer to give priority to purchase the Sold Shares on the terms and conditions set forth in the Notice of Transfer
(subject to the provisions of Clause 4.1(b)(ii) below) (the “Preemptive Right”). The Purchase Notice shall state the amount of Sold Shares to be purchased by each Investor. 

 

	 	(ii)	 The number of Sold Shares available for each Investor: Where each Investor claims to exercise the Preemptive
Right, the respective purchase proportion shall be determined through consultation. If no agreement can be reached, the Preemptive Right shall be exercised in proportion to the total number of shares held by the investors who claim the Preemptive
Right at the time of transfer, which shall be equal to the total number of shares held by the Investors who claim the Preemptive Right at that time. 

  

	 	(iii)	 If an ongoing Transfer arises as a result of enforcement of law or another involuntary transfer (including a
transfer arising from death, divorce, separation or insolvency), the price per share should be the higher of the following: (A) the original purchase price paid by the Disposing Shareholder for the Sold Shares (subject to such adjustments as
may be appropriate in the case of share splits, dividends distribution, mergers and the like), but not less than the nominal value, or (B) the fair market value (not less than the nominal value) of the Sold Shares, as determined by the Board of
Directors, taking into account such factors as the Company’s current income and future prospects and reflecting the current value of the Shares, and determined by the Company within thirty (30) Working Days of receipt of the Notice of
Transfer. If the Disposing Shareholder or the executor of the Disposing Shareholder disagrees with the valuation determined by the Board of Directors, then the Disposing Shareholder or the executor of the Disposing Shareholder shall have the right
to entrust an independent appraiser agreed by the Company and the Disposing Shareholder or the executor of the Disposing Shareholder to determine the valuation, and the appraiser’s expenses shall be shared equally between the Company and the
Disposing Shareholder or the estate of the Disposing Shareholder. 

  
 10 

	4.2	 Co-Sale Rights. If any investor fails to exercise the Preemptive
Right mentioned in the preceding paragraph, within ten (10) Working Days after the expiration of the Preemptive Period (the “Co-Sale Period”), such Investor may give a written notice (the
“Co-Sale Notice”) to the Disposing Shareholder and the Company requiring the Investor’s shares in the Company to be sold to a potential transferee of the Sold Shares (the “Co-Sale Rights”) in accordance with the sale price of the Sold Shares and other terms and conditions set out in the Notice of transfer. Investor’s Sellable Shares = (the percentage of Sold Shares of
Disposing Shareholder to all of their shares * the number of shares held by the Investor). If a potential transferee of Sold Shares refuses to purchase any number of shares to be sold by the investor, or the potential transferee fails to complete
the purchase of the shares to be sold by the Investor before or at the same time as the purchase of the Sold Shares is completed, the Disposing Shareholder shall not sell any of the Sold Shares to the potential transferee unless the Disposing
Shareholder completes the purchase of the Investor’s shares to be sold prior to or at the same time as the sale price (not less than the nominal value) and other terms and conditions set out in the Notice of Transfer. 

 

	4.3	 Not Exercising Rights. If Investors fail to exercise the Preemptive Right under Clause 4.2 and the Co-Sale Right under Clause 4.3, the Disposing Shareholder shall sell any remaining Sold Shares to the third party transferee identified in the Notice of Transfer within ninety (90) days after the expiration of
the Co-Sale Period, on terms and conditions (including the Purchase Price) not favorable to the Purchaser as set forth in the Notice of Transfer. As a condition for the effective Transfer of the Sold Share,
the third party transferee shall provide the Company and all Shareholders of the Company with written consent to be bound by and to comply with this Agreement, including but not limited to all provisions of this Clause 4, as if the transferee were a
Disposing Shareholder in this Agreement and to comply with the terms of the transferee under which the Equity Securities are issued. If the Disposing Shareholder fails to complete the sale or disposal of the Sold Shares within ninety (90) days
after the expiration of the Co-Sale Period, or the Company proposes to sell the Sold Shares on more favorable terms than those set out in the Notice of Transfer, or the Company proposes to sell the Sold Shares
to a party other than a third party transferee as identified in the Notice of Transfer, the Disposing Shareholders shall not sell any Sold Shares until the Investors have re-exercised their Preemptive Rights
and Co-Sale Rights under this Clause 4. Moreover, whether any investor exercises a Preemptive Right or a Co-Sale Right over the Sold Shares of the Disposing Shareholder
shall not adversely affect the subsequent purchase of Equity Securities by the Investor from any Disposing Shareholder. Any subsequent Transfer of any Sold Shares proposed by the Disposing Shareholders shall again be subject to the Preemption and Co-Sale Rights of the Investors and the relevant Disposing Shareholders shall be required to comply with the procedures set out in this Clause 4. 

 

	4.4	 Legend. 

  
 11 

	 	(a)	 Each certificate issued to each Existing Major Shareholder representing the Ordinary Share shall endorse the
following legend: 

 “The sale, pledge, mortgage or transfer of the securities represented by this Certificate is
subject to specific restrictions on the transfer under the Shareholders’ Agreement, a copy of which may be obtained by written request to the Secretary of the Company.” 

 

	 	(b)	 The Parties agree that the Company may direct its Transfer agent to impose transfer restrictions on the Shares
represented by the certificates of the legend referred to in Clause 4.5 (a) above for the purpose of enforcing the terms of this Agreement, and the Company agrees to do so forthwith. The legend shall be removed at the termination of the provisions
of this Clause 4. 

  

	4.5	 Transfer of Investor’s Equity. Each Investor shall not be subject to any restrictions on the
Transfer of his/her Equity Securities in the Company (provided that such Transfer shall not be made to a competitor of the Company or a transferee associated with the competitor). 

 

	4.6	 Term. This Clause 4 shall terminate at the time of completion of the Qualified Public Offering.

  

	5.	 TRANSFER AND AMENDMENT 

 

	5.1	 Transfer. When each Investor transfers the shares of the Company he/she holds, all and any rights and
interests relating to such shares may be fully transferred. 

  

	5.2	 Rights of Amendment. Any terms of this Agreement may be amended only with the written consent of each
Existing Major Shareholder and Investors. Any amendment or waiver that becomes effective pursuant to this Clause 5.2 shall be binding upon the Parties hereto and their respective transferees. 

 

	6.	 COMPENSATION 

  

	6.1	 The Founders and the Group Companies shall indemnify, defend and protect Investors, jointly and separately,
against all Losses arising directly or indirectly from, in connection with or incidental to any violation of any representations, warranties, undertakings or agreements made in this Agreement or in any transaction agreement to be signed in this
Agreement. The compensation shall first be borne by each Group Company. If each Group Company cannot make compensation after its best efforts, the Founders shall perform the compensation obligation. 

 

	7.	 CONFIDENTIALITY AND NON-DISCLOSURE 

 

	7.1	 Confidentiality. Shall be executed in accordance with the Confidentiality Agreement signed between the
Company and Shanghai EMPOWER Investment Management Co., Ltd. 

  

	8.	 VOTING RIGHTS, PROTECTIVE CLAUSES AND DIVIDEND RIGHTS 

  
 12 

	8.1	 Voting Rights. Except as otherwise provided in this Agreement, the Articles of Association as defined
below and Applicable Law, any Ordinary Share shall have one vote on any matter of the Company to be resolved by the Shareholders and each Investor shall vote and resolve as a series of Shareholders with each Existing Shareholder. If the proportion
of Equity Securities held by the Shareholders present at the Shareholders’ meeting reaches two thirds (2/3) of the Equity Securities already issued at that time, the resolution made at the shareholders’ meeting shall be valid. Each
Shareholder’s Representative may attend a meeting of the Shareholders through any teleconference or other means of communication available to all Shareholders’ Representatives attending the meeting of the Shareholders. Where a resolution
of the Shareholders’ meeting is made by means of a written resolution without convening a Shareholders’ meeting, such written resolution must be signed by all the Shareholders of the Company for the purpose of validity.

  

	8.2	 Protective Clauses that Require the Approval of Majority Shareholders. In accordance with the
Company’s latest Articles of Association, the following actions of any Group Company require the prior consent of the majority shareholder who holds a total of two-thirds (2/3) of the issued Equity
Securities of the Company: 

  

	 	(a)	 increase or decrease the authorized share capital, issued share capital or registered capital;

  

	 	(b)	 any Equity Securities, options to purchase Equity Securities, new issues relating to Equity Securities or debt
securities; 

  

	 	(c)	 any liquidation, dissolution, winding-up, recapitalization,
reorganization, consolidation, separation, listing or bankruptcy proceedings; 

  

	 	(d)	 any material change to the Articles of Association or other Organizational Document; 

 

	 	(e)	 the reclassification of any issued Equity Security so that its priority over dividends or assets is higher than
or equal to that of the shares of the Company held by individual Investors. 

  

	8.3	 Dividend Rights. Investors have the right to participate in any dividends and other distributions of the
Company in proportion to their Equity Securities held in the Company and other Shareholders. 

  

	9.	 ANTI-DILUTION 

 

	9.1	 If the Company issues any New Shares or any additional capital, except for the executive employee incentive
plan approved by the Board of Directors, and the unit price of such New Shares is lower than the Price Per Share for Investors, as an anti-dilution protection measure, the Investor shall have the right to further acquire the shares issued by the
Company at zero consideration or at the lowest consideration permitted by other laws to ensure that the Investor’s rights and interests in the Company are not diluted. 

 

	10.	 OTHER CLAUSES 

  
 13 

	10.1	 If the investment cost of Investors to the Group Company is inconsistent with the actual investment cost, where
the Investors are required to bear additional tax costs due to the inconsistent tax basis in the future reorganization or realization of investment in the Group Company, the Company and the Founders shall take all necessary measures to ensure that
the Investors shall not incur any additional costs or Losses as a result thereof. Such measures shall include, but are not limited to: 1. Ensuring that Investors shall not bear such tax costs and other Losses; 2. Ensuring that Investors shall
receive after-tax income calculated on the basis of actual investment costs (including, but not limited to, raising the next valuation, etc.). If the Company and the Founders fail to achieve the effect agreed
in the foregoing terms and conditions through all efforts, the Parties concerned shall, with the written consent of the Investors, negotiate and resolve the matter separately under the principles of fairness and impartiality. In the event that the
Parties fail to resolve the matter through negotiation within thirty (30) calendar days, the Company and the Founders shall be jointly and severally liable for all costs and Losses borne by the Investors. 

 

	10.2	 The Company undertakes to EMPOWER Investment that, except for the circumstances in which the Company has
disclosed to EMPOWER Investment, there is no superiority over the undertaking in relation to the rights under this Agreement in any agreement between the Company and other natural persons and institutions that subscribed for the shares of the
Company before the signing of this Agreement. Otherwise, EMPOWER Investment shall be entitled to equal rights in accordance with these terms. 

  

	10.3	 Registration Rights. When any Investor requests, each Group Company, Existing Major Shareholders shall
cause the Group Company planning to make a public offering to grant the Investor (to the reasonable satisfaction of the Investor) the right to register with the Securities and Exchange Commission for all securities held by the Investor (including,
but not limited to, three (3) times of demand registration and an unlimited number of “piggyback” and F-3/S-3 Form registration rights (or any subsequent
registry under the Securities Act), or an equivalent or similar right to register any issue in any other jurisdiction of securities of any Group Company in respect of which the Group Company undertakes to make a public offering or to list such
securities on a recognized stock exchange. 

  

	11.	 GENERAL CLAUSES 

 

	11.1	 Binding Force; Transfer. Subject to Clause 5.1, this Agreement shall be binding upon and beneficial to
the heirs, successors, executors and administrators of the Parties hereto, as well as the Transferee. However, this Agreement shall not be transferred by any party to this Agreement (other than Investors) without the prior written consent of the
respective Investors. This Agreement and the rights and obligations hereunder may be transferred by any Investor to any Person without the prior written consent of the other Parties to this Agreement, provided that such Person has signed a contract
of compliance and consented to be bound by this Agreement. 

  

	11.2	 Applicable Law. This Agreement shall be governed by and construed in all respects in accordance with the
laws of Hong Kong. 

  

	11.3	 Dispute Resolution. 

  
 14 

	 	(a)	 Any dispute, contradiction or claim arising out of or relating to this Agreement, or the interpretation, breach
of contract, termination or validity of this Agreement (each referred to as a “Dispute”) shall be settled first through consultation by the Parties to the Dispute. Such consultation shall commence immediately upon written notice of any
request for consultations by either Party to the Dispute. 

  

	 	(b)	 If the Dispute is not resolved within fifteen (15) days from the date of the aforesaid notice, either
Party to the Dispute may submit it to arbitration by giving notice to the other Parties to the Dispute (the “Notice of Arbitration”). 

  

	 	(c)	 The arbitration shall be submitted to the Shanghai Arbitration Commission for final award.

  

	 	(d)	 Either Party to the arbitration shall cooperate with the other Parties to the arbitration and, subject to its
obligation of confidentiality, such party shall fully disclose and allow full access to all information and documents required by the other Party in connection with the arbitration proceedings. 

 

	 	(e)	 Unless otherwise awarded by the arbitral tribunal, the costs of the arbitration shall be borne by the losing
Party. 

  

	 	(f)	 In the event of a Dispute and the arbitration thereof, the Parties shall continue to perform their respective
obligations and shall be entitled to exercise their rights under this Agreement, except in the case of such Dispute. 

  

	 	(g)	 The award of the arbitral tribunal shall be final and binding on the Parties, and the prevailing Party shall
apply to the jurisdictional court for enforcement of the award. 

  

	 	(h)	 In the course of the arbitral tribunal’s hearing of the Dispute, this Agreement shall continue to be
performed except for the part of the Dispute that is in it. 

  

	11.4	 Complete Agreement. Except as disclosed by the Company to EMPOWER Investment prior to the signing of
this Agreement, this Agreement, the Subscription Agreement and any other Transaction Agreement contemplated by this Agreement and the annexes and schedules hereto constitute the entire understanding and agreement between the parties and supersede
all prior written or oral understandings or agreements with respect to the subject matter hereof. 

  

	11.5	 Notification. Except as otherwise provided herein, all notices, requests, waivers or other
communications made pursuant to this Agreement shall be in writing and shall be deemed to have been duly served at the time of delivery if (a) delivered personally at the address set forth in Appendix A to this Agreement; (b) by
facsimile transmission at the number listed in Appendix A to this Agreement, upon receipt of confirmation of facsimile correctness (and a record of receipt of a written reply); (c) by airmail or registered mail (requiring a receipt, postage
prepaid, address as set out in Appendix A to this Agreement and with a sign-off record), five (5) Working Days after the date of delivery; (d) by overnight courier service (postage prepaid, sent at
the address set forth in Appendix A to this Agreement and guaranteed to be delivered on the following Working Day and with a sign-off record), three (3) Working Days after the date of delivery,
provided that the sending Party obtains a confirmation of delivery from the delivery agency; or (e) if the e-mail is sent in accordance with the e-mail address
listed in Appendix A to this Agreement, at the time the e-mail is normally sent (and there is a record of receipt of the e-mail reply). 

  
 15 

 If communications under this Agreement are transmitted by facsimile, the sending Party shall
immediately confirm each communication faxed pursuant to this Agreement by telephone to the received Party, but the failure to do so shall not affect the validity of such communications. For the purposes of this Clause 11.5, either Party may change
or supplement the address set out in Appendix A or designate additional addresses by giving written notice to the other Parties in the manner described above. 
  

	11.6	 Delay or omission. Either Party delays or fails to exercise the rights, powers or relieves conferred
upon it by the other Party for breach or non-performance of this Agreement, shall not prejudice the right, powers or relief of that Party, nor shall it be deemed to be a waiver of or acquiescence in the breach
or non-performance or any subsequent similar breach or non-performance, nor shall it be deemed to be a waiver of any other breach or
non-performance occurring before or after that date. A waiver, permission, consent, or approval of a breach or non-performance of any of the nature or characteristics of
this Agreement or waiver of any of the terms or conditions of this Agreement must be made in writing and shall be valid only to the extent specified in such writing. Any relief provided to either Party under this Agreement, by law or otherwise,
shall be cumulative but not optional. 

  

	11.7	 Severability. If any provision of this Agreement is invalid or unenforceable, it shall be construed so
far as is practicable to enable it to be executed and to enable the transaction under this Agreement to be completed on substantially the same terms as previously stated. If there is no workable interpretation for the retention of this clause, it
shall be severed from the remainder of this Agreement, which shall remain in full force and effect unless the severed clause is essential to the rights and interests intended by the Parties. In such circumstances, the Parties shall use their best
endeavors to negotiate in good faith an effective and enforceable alternative Clause or Agreement in order to achieve to the fullest extent on the intentions of the Parties at the time of entering into this Agreement. 

 

	11.8	 Shareholder’s Agreement Prevails. In the event of any inconsistency between the
clauses of this Agreement and the Articles of Association, the clauses of this Agreement shall prevail for the sole benefit of the Shareholders of the Company. Upon the discovery of such inconsistencies, the Parties agree to take all necessary or
desirable measures for consultation to eliminate such inconsistencies to the fullest extent permitted by Applicable Law. 

  

	11.9	 Come into Force. This Agreement shall come into force on the date of delivery upon signature by the
Parties. 

  

	11.10	 Copy. This Agreement may be signed on any number of texts, all of which are originals, but all of which
together constitute one document. 

  
 16 

 In view of this, the Parties hereto have caused their duly authorized representatives to
sign this Agreement as of the date on the head of the text. Place of execution of this Agreement: Shanghai, China. 
 Group Companies: 

 

	
	AnPac Bio-Medical Science Co., Ltd.
	
	Signature: /s/ Chris Chang Yu                    
	Name: Chris Chang Yu
	Title: Chairman of Board
	
	Zhejiang AnPac Bio-Medical Science Co., Ltd. (Seal)
	
	Signature: /s/ Chris Chang Yu                    
	Name: Chris Chang Yu
	Title: Legal Representative
	
	Changhe Bio-Medical Science (Yangzhou) Co., Ltd. (Seal)
	
	Signature: /s/ Chris Chang Yu                    
	Name: Chris Chang Yu
	Title: Legal Representative

  
 17 

 In view of this, the Parties hereto have caused their duly authorized representatives to
sign this Agreement as of the date on the head of the text. Place of execution of this Agreement: Shanghai, China. 
 Group Companies: 

 

	
	Changwei System Technology (Shanghai) Co., Ltd. (Seal)
	
	Signature: /s/ Chris Chang Yu                    
	Name: Chris Chang Yu
	Title: Legal Representative
	
	AnPac Bio-Medical Science (Shanghai) Co., Ltd. (Seal)
	
	Signature: /s/ Chris Chang Yu                    
	Name: Chris Chang Yu
	Title: Legal Representative
	
	Shanghai Xinshenpai Technology Co., Ltd. (Seal)
	
	Signature: /s/ Chris Chang Yu                    
	Name: Chris Chang Yu
	Title: Legal Representative

  
 18 

 In view of this, the Parties hereto have caused their duly authorized representatives to
sign this Agreement as of the date on the head of the text. Place of execution of this Agreement: Shanghai, China. 
 Group Companies: 

Lishui AnPac Medical Laboratory Co., Ltd. 
  

			
	Signature:	 	 /s/ Chris Chang Yu

			
	Name:	 	Chris Chang Yu

			
	Title:	 	Legal Representative

 Chengdu Lipaishen
Bio-Medical Science Co., Ltd. (Seal) 
  

			
	Signature:	 	 /s/ Xuedong Du

			
	Name:	 	Xuedong Du

			
	Title:	 	Legal Representative

 ANPAC TECHNOLOGY USA CO., LTD. 

 

			
	Signature:	 	 /s/ Chris Chang Yu

			
	Name:	 	Chris Chang Yu

			
	Title:	 	Legal Representative

  
 19 

 In view of this, the Parties hereto have caused their duly authorized representatives to
sign this Agreement as of the date on the head of the text. Place of execution of this Agreement: Shanghai, China. 
 Existing Major Shareholders:

 Chris Chang Yu 
  

			
	Signature:	 	 /s/ Chris Chang Yu

Lin Yu 
  

			
	Signature:	 	 /s/ Lin Yu

CRS Holdings Inc. 
  

			
	Signature:	 	 /s/ Chris Chang Yu

			
	Name:	 	Chris Chang Yu

			
	Title:	 	President

  
 20 

 In view of this, the Parties hereto have caused their duly authorized representatives to
sign this Agreement as of the date on the head of the text. Place of execution of this Agreement: Shanghai, China. 
 Investor: 

EMPOWER FUND I, L.P. 
  

			
	Signature:	 	 /s/ Yu Junhan

	Name:	 	Yu Junhan
	Title:	 	Managing Partner

  
 21 

 Appendix A 

Notice address 
 For the purposes of the
Notice Clauses set out in this Agreement, the initial addresses of the Parties are as follows: 
  

	
	 To Existing Major Shareholders:

	
	 Address:

	 Zip code:

	 E-mail:

	 Addressee:

	
	 To any Group Companies:

	
	 Address:

	 Zip code:

	 E-mail:

	 Addressee:

	
	 To Investors:

	
	EMPOWER FUND I, L.P.
	
	 Address:

	 Fax:

	 E-mail:

	 Attention:

  
 22

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00301-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00301-of-00352.parquet"}]]